Home › Compare › HYMTF vs ABBV
HYMTF yields 1.40% · ABBV yields 3.06%● Live data
📍 HYMTF pulled ahead of the other in Year 5
Combined, HYMTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HYMTF + ABBV for your $10,000?
Hyundai Motor Company, together with its subsidiaries, manufactures and distributes motor vehicles and parts worldwide. It operates through Vehicle, Finance, and Others segments. The company offers cars under the Azera, Sonata, Veloster, Veloster N, i30 Fastback N, The new i30, i30 N, The all-new Elantra, Accent, i20 N, i20, The all-new Elantra N, and i10 names; and SUVs under the Palisade, Santa Fe, The all-new Tucson, Creta, The new Kona, KONA N, and Venue names. It also provides commercial vehicles under the STARIA, H-1, and H-100 names; and eco vehicles under the IONIQ 5, NEXO, Santa Fe Hybrid/Plug-in Hybrid, The all-new Tucson Hybrid, The all-new Tucson Plug-in Hybrid, KONA Electric, The all-new Elantra Hybrid, IONIQ Plug-in Hybrid, IONIQ Electric, IONIQ Hybrid, and The new i30 Hybrid names. In addition, the company offers trucks, buses, vans, engines; vehicle financing, credit card processing, and other financing activities; train manufacturing services and other activities; and marketing, engineering, mobility, and insurance services, as well as operates a football club. Further, it is involved in real estate development; research and development; and investment activities. Hyundai Motor Company was incorporated in 1967 and is headquartered in Seoul, South Korea.
Full HYMTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.